Dynakin is a biopharmaceutical CRO (Contract Research Organization) addressing drug development issues across two dimensions, GLP Bioanalysis and Model (and simulation) Based Drug Development (MBDD) decision making with our DMC group. The company has extensive knowledge in performing and in accompanying partners and clients through the R&D for drug development from pre-clinical, FTIM, and Phase I up to Phase III and IV clinical trials. Among the services already offered our clients are GLP services for Oncology, Allergies and Immunosuppression then also MBDD and metadata based consulting using Modeling & Simulation for strategic decision making in Alzheimer’s, Rheumatoid Arthritis, Allergies, Oncology, Immunosuppression, Inflammatory Bowel Disease, Chronic Obstructive Pulmonary Disease.

Find out more...

 Download a brochure

View a presentation